Venn diagram showing<unk>  as a sub-field of genomics, microbiology, and pharmacology.<unk> , first used in 2010, is defined as the effect of microbiome variations on drug disposition, action, and toxicity.<unk>  is concerned with the interaction between xenobiotics, or foreign compounds, and the gut microbiome. It is estimated that over 100 trillion prokaryotes representing more than 1000 species reside in the gut. Within the gut, microbes help modulate developmental, immunological and nutrition host functions. The aggregate genome of microbes extends the metabolic capabilities of humans, allowing them to capture nutrients from diverse sources. Namely, through the secretion of enzymes that assist in the metabolism of chemicals foreign to the body, modification of liver and intestinal enzymes, and modulation of the expression of human metabolic genes, microbes can significantly impact the ingestion of xenobiotics. Efforts to understand the interaction between specific xenobiotics and the microbiome have traditionally involved the use of in vivo as well as in vitro models. Recently, next generation sequencing of genomic DNA obtained from a community of microbes has been used to identify organisms within microbial communities, allowing for accurate profiles of the composition of microbes within an environment. Initiatives such as the Human Microbiome Project (HMP) have aimed to characterize the microbial composition of the oral, gut, vaginal, skin and nasal environments. This and other microbiome characterization projects have accelerated the study of<unk> . An extensive understanding of the microbiome in the human body can lead to the development of novel therapeutics and personalized drug treatments that are not potentiated or activated by processes carried out by the microbiome.
Pharmacomicrobiomics
Pharmacometabolomics
Metabolomics
Risk panel
Biomonitoring
Nutriepigenomics
Anthropometric cosmetology
Foodomics